NCT04022421Unknown不适用
The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Prevention of the recurrence of thrombotic events
研究概览
简要总结
Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients diagnosed with Behcet's disease on any DMARDs
排除标准
- •Patients with critical conditions
- •Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.
研究组 & 干预措施
hydroxychloroquine arm
Experimental
干预措施: Hydroxychloroquine (Drug)
结局指标
主要结局
Prevention of the recurrence of thrombotic events
时间窗: 6 months- one year
number of relapses is expected to fall with the longterm use of the drug
次要结局
未报告次要终点
研究者
Alaa Abdelkhalik Ahmed Mohamed
Principal Investigator
Assiut University
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Hydroxychloroquine in Mild Graves' OrbitopathyGraves OphthalmopathyNCT05126147National Taiwan University Hospital108
招募中
2 期
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)Alport Syndrome, X-LinkedNCT04937907Shanghai Children's Hospital50
撤回
3 期
Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health ProfessionalsCOVID19Sars-CoV2HydroxychloroquineProphylaxisHealthcare WorkerNCT04349228Abderrahmane Mami Hospital
已完成
早期 1 期
Treatment of Muscle Cramps in Patients With Liver CirrhosisMuscle CrampsLiver CirrhosisNCT01495403Mayo Clinic3
暂停
4 期
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of CareCOVID-19Corona Virus InfectionSARS-CoV-22019-nCoV2019 Novel CoronavirusNCT04334967Providence Health & Services13